In the US, approved another type of gene therapy for cancer - ForumDaily
The article has been automatically translated into English by Google Translate from Russian and has not been edited.
Переклад цього матеріалу українською мовою з російської було автоматично здійснено сервісом Google Translate, без подальшого редагування тексту.
Bu məqalə Google Translate servisi vasitəsi ilə avtomatik olaraq rus dilindən azərbaycan dilinə tərcümə olunmuşdur. Bundan sonra mətn redaktə edilməmişdir.

In the US, approved another type of gene therapy for cancer

Фото: Depositphotos

U.S. regulators on Wednesday approved a second gene therapy for blood cancer, a one-time, personalized treatment for aggressive lymphoma in adults. Writes about this New York Times.

Food and Drug Administration (FDA) has authorized the sale of the drug Kite pharma. It uses the same technology as CAR-T, which underlies first gene therapyapproved in the US in August for the treatment of leukemia in children with the drug Novartis Pharmaceuticals.

“Over the decades, gene therapy has evolved from a promising concept to a practical solution to deadly and largely incurable forms of cancer,” FDA Commissioner Dr. Scott Gottlieb said in a statement.

According to the pharmacist Gilead Sciencesa medicine called Yescartawill cost $ 373 000 for one patient. This month Kite became a subsidiary Foster CityCalifornian Gilead.

Technology is called CAR-T and is made by extracting the cells of the immune system from the patient’s blood.

These cells—T lymphocytes—are then genetically reprogrammed to find and destroy cancer cells.

The modified lymphocytes are then returned to the patient’s body, where their number increases each time they collide with cancer cells.

That is why these immunotherapy procedures are called “living medicines».

"Today's Approval Yescarta “This is a very important advance for patients with lymphoma and cancer in general,” said Luis Degennaro, president of the Leukemia and Lymphoma Society. “Immunotherapy is dramatically changing the way we treat blood cancers.”

Drug therapy Kite pharma Designed for patients with three types of aggressive or fast-growing large B-cell lymphoma.

Preparation Yescarta, also known as axicabtagene ciloleucelwas approved for patients who have already undergone at least two courses of anticancer drugs that either did not work for them or eventually stopped working.

In the key test Yescarta Participated 101 patient. Around 72% was diagnosed with a decrease in cancer, and in half of the months after 8, no cancer was found.

Scientists think they can overcome a significant number of tumors within a few years.

Read also on ForumDaily:

Top worst nutritional supplements in America

Ten medicines that contribute to weight gain

30 million Americans consume water with heavy metals and toxins.

Miscellanea In the U.S. cancer
Subscribe to ForumDaily on Google News

Do you want more important and interesting news about life in the USA and immigration to America? — support us donate! Also subscribe to our page Facebook. Select the “Priority in display” option and read us first. Also, don't forget to subscribe to our РєР ° РЅР ° Р »РІ Telegram  and Instagram- there is a lot of interesting things there. And join thousands of readers ForumDaily New York — there you will find a lot of interesting and positive information about life in the metropolis. 



 
1083 requests in 1,182 seconds.